-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA approves Roche's Wilserdly combination for advanced breast cancer

PUBT·11/16/2026 22:15:57
Listen to the news
FDA approves Roche's Wilserdly combination for advanced breast cancer
  • FDA approves Roche’s Wilserdly with everolimus for adults with previously treated ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
  • The combination reduced disease progression or death risk by 62% versus standard endocrine therapy with everolimus in ESR1-mutated patients.
  • A separate FDA review of Wilserdly for adjuvant breast cancer treatment has a decision deadline of November 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161715OMX_____CNEWS_EN_GNW1001303975_en) on November 16, 2026, and is solely responsible for the information contained therein.